Marker Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. CEO Dr. Juan Vera will lead a fireside chat on September 10, 2025, from 12:30 to 1:00 p.m. EDT. The company will discuss its MAR T cell platform and updates from the Phase 1 APOLLO study. Interested investors can view the live webcast of the presentation on Marker's Investor Relations website.

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company's CEO, Dr. Juan Vera, will lead a fireside chat on September 10, 2025, from 12:30 to 1:00 p.m. EDT, discussing the company's Multi-Antigen Recognizing (MAR) T cell platform and updates from the Phase 1 APOLLO study. Interested investors can view the live webcast of the presentation on Marker's Investor Relations website.

During the fireside chat, Dr. Vera and Marker's management team will discuss the company's MAR T cell platform, which has shown promising results in clinical trials. The platform focuses on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The company's lead product, MT-601, targets six tumor-specific antigens and has demonstrated durable objective response rates in patients with lymphoma who have relapsed after anti-CD19 CAR-T cells or where CAR-T cell therapy is not an option.

The Phase 1 APOLLO study, which is currently underway, has shown positive clinical data. The study revealed that MT-601 demonstrated a 66% objective response rate in patients with Non-Hodgkin Lymphoma (NHL), with 50% achieving complete responses. The treatment also showed a favorable safety profile across all evaluated doses. The study included 24 B-cell lymphoma patients treated across seven U.S. clinical sites, comprising 15 patients with NHL and 9 with Hodgkin Lymphoma (HL). Among the 12 NHL patients evaluated, eight showed objective responses, with six demonstrating complete responses. These NHL patients had previously undergone a median of five prior lines of therapy, including CAR-T cells and bispecific antibodies.

The company's MAR T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research. Marker Therapeutics has been awarded over $30 million in non-dilutive funding to date, including from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Cancer Prevention and Research Institute of Texas (CPRIT).

Investors interested in attending the fireside chat can register and access the webcast through Marker's Investor Relations website under "Events and Presentations."

References:

[1] https://www.biospace.com/press-releases/marker-therapeutics-to-participate-in-a-fireside-chat-at-the-h-c-wainwright-27th-annual-global-investment-conference
[2] https://www.investing.com/news/stock-market-news/marker-therapeutics-stock-soars-on-promising-phase-1-lymphoma-study-data-93CH-4211000
[3] https://www.marketscreener.com/news/marker-therapeutics-corporate-presentation-ce7c50d9d88cf721